The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Open accessAbstract
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,946
Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,447
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Self-citationEverolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Self-citationSunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Rinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,935
Self-citationKwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
Self-citationFalconi, M., Eriksson, B., Kaltsas, G., Bartsch, D. K., Capdevila, J., Caplin, M., Kos-Kudla, B., Kwekkeboom, D., Rindi, G., Klöppel, G., et al. (2016) · Neuroendocrinology · doi:10.1159/000443171 · Cited by 1,362
Self-citationYao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., Tomasek, J., Raderer, M., Lahner, H., Voi, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00817-x · Cited by 1,292
Self-citationPavel, M. E., Hainsworth, J. D., Baudin, E., Peeters, M., Hörsch, D., Winkler, R. E., Klimovsky, J., Lebwohl, D., Jehl, V., Wolin, E. M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61742-x · Cited by 1,058
Self-citationGabriel, M., Decristoforo, C., Kendler, D., Dobrozemsky, G., Heute, D., Uprimny, C., Kovacs, P., Von Guggenberg, E., Bale, R., & Virgolini, I. J. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.035667 · Cited by 1,010
Whole-genome landscape of pancreatic neuroendocrine tumours
Initiative, A. P. C. G., Scarpa, A., Chang, D. K., Nones, K., Corbo, V., Patch, A.-M., Bailey, P., Lawlor, R. T., Johns, A. L., Miller, D. K., et al. (2017) · Nature · doi:10.1038/nature21063 · Cited by 999
Self-citationMoertel, C. G., Lefkopoulo, M., Lipsitz, S., Hahn, R. G., & Klaassen, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202203260804 · Cited by 976
Yao, J. C., Lombard-Bohas, C., Baudin, E., Kvols, L. K., Rougier, P., Ruszniewski, P., Hoosen, S., St. Peter, J., Haas, T., Lebwohl, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2669 · Cited by 647
ESMO-magnitude of clinical benefit scale version 1.1
Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M. J., & de Vries, E. G. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx310 · Cited by 641
Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 636
Brabander, T., van der Zwan, W. A., Teunissen, J. J. M., Kam, B. L. R., Feelders, R. A., de Herder, W. W., van Eijck, C. H. J., Franssen, G. J. H., Krenning, E. P., & Kwekkeboom, D. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2743 · Cited by 614
Self-citationGarcia-Carbonero, R., Sorbye, H., Baudin, E., Raymond, E., Wiedenmann, B., Niederle, B., Sedlackova, E., Toumpanakis, C., Anlauf, M., Cwikla, J. B., et al. (2016) · Neuroendocrinology · doi:10.1159/000443172 · Cited by 611
Self-citationRecommendations for management of patients with neuroendocrine liver metastases
Frilling, A., Modlin, I. M., Kidd, M., Russell, C., Breitenstein, S., Salem, R., Kwekkeboom, D., Lau, W.-Y., Klersy, C., Vilgrain, V., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70362-0 · Cited by 527
Sundin, A., Arnold, R., Baudin, E., Cwikla, J. B., Eriksson, B., Fanti, S., Fazio, N., Giammarile, F., Hicks, R. J., Kjaer, A., et al. (2017) · Neuroendocrinology · doi:10.1159/000471879 · Cited by 501
Self-citationBinderup, T., Knigge, U., Loft, A., Federspiel, B., & Kjaer, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1759 · Cited by 489
TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study
Rindi, G., Falconi, M., Klersy, C., Albarello, L., Boninsegna, L., Buchler, M. W., Capella, C., Caplin, M., Couvelard, A., Doglioni, C., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs208 · Cited by 452
Self-citationMODLIN, I. M., PAVEL, M., KIDD, M., & GUSTAFSSON, B. I. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04174.x · Cited by 410
Self-citationAnderson, M. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)01272-7 · Cited by 399
Strosberg, J., Wolin, E., Chasen, B., Kulke, M., Bushnell, D., Caplin, M., Baum, R. P., Kunz, P., Hobday, T., Hendifar, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.5865 · Cited by 390
Self-citationDromain, C., de Baere, T., Lumbroso, J., Caillet, H., Laplanche, A., Boige, V., Ducreux, M., Duvillard, P., Elias, D., Schlumberger, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.013 · Cited by 389
Rinke, A., Wittenberg, M., Schade-Brittinger, C., Aminossadati, B., Ronicke, E., Gress, T. M., Müller, H.-H., Arnold, R., & for the PROMID Study Group (2017) · Neuroendocrinology · doi:10.1159/000443612 · Cited by 377
Kwekkeboom, D. J., Krenning, E. P., Lebtahi, R., Komminoth, P., Kos-Kudła, B., de Herder, W. W., & Plöckinger, U. (2009) · Neuroendocrinology · doi:10.1159/000225951 · Cited by 349
Self-citationGastroenteropancreatic high‐grade neuroendocrine carcinoma
Sorbye, H., Strosberg, J., Baudin, E., Klimstra, D. S., & Yao, J. C. (2014) · Cancer · doi:10.1002/cncr.28721 · Cited by 347
Hicks, R. J., Kwekkeboom, D. J., Krenning, E., Bodei, L., Grozinsky-Glasberg, S., Arnold, R., Borbath, I., Cwikla, J., Toumpanakis, C., Kaltsas, G., et al. (2017) · Neuroendocrinology · doi:10.1159/000475526 · Cited by 336
Self-citationGouya, H., Vignaux, O., Augui, J., Dousset, B., Palazzo, L., Louvel, A., Chaussade, S., & Legmann, P. (2003) · American Journal of Roentgenology · doi:10.2214/ajr.181.4.1810987 · Cited by 312
90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
Bushnell, D. L., O'Dorisio, T. M., O'Dorisio, M. S., Menda, Y., Hicks, R. J., Van Cutsem, E., Baulieu, J.-L., Borson-Chazot, F., Anthony, L., Benson, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8585 · Cited by 306
Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome
Kulke, M. H., Hörsch, D., Caplin, M. E., Anthony, L. B., Bergsland, E., Öberg, K., Welin, S., Warner, R. R. P., Lombard-Bohas, C., Kunz, P. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.2780 · Cited by 303
Self-citationYao, J. C., Pavel, M., Lombard-Bohas, C., Van Cutsem, E., Voi, M., Brandt, U., He, W., Chen, D., Capdevila, J., de Vries, E. G. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.0702 · Cited by 274
Self-citationNorlén, O., Stålberg, P., Öberg, K., Eriksson, J., Hedberg, J., Hessman, O., Janson, E. T., Hellman, P., & Åkerström, G. (2012) · World Journal of Surgery · doi:10.1007/s00268-011-1296-z · Cited by 260
Self-citationFrilling, A., Li, J., Malamutmann, E., Schmid, K.-W., Bockisch, A., & Broelsch, C. E. (2009) · British Journal of Surgery · doi:10.1002/bjs.6468 · Cited by 257
Perren, A., Couvelard, A., Scoazec, J.-Y., Costa, F., Borbath, I., Delle Fave, G., Gorbounova, V., Gross, D., Grossman, A., Jensen, R. T., et al. (2017) · Neuroendocrinology · doi:10.1159/000457956 · Cited by 250
Self-citationCaplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., et al. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-15-0490 · Cited by 230
Self-citationThe Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors
Mazzaferro, V, Sposito, C., Coppa, J., Miceli, R., Bhoori, S., Bongini, M., Camerini, T., Milione, M., Regalia, E., Spreafico, C., et al. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13831 · Cited by 220
Geijer, H., & Breimer, L. H. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2482-z · Cited by 212
d’Assignies, G., Fina, P., Bruno, O., Vullierme, M.-P., Tubach, F., Paradis, V., Sauvanet, A., Ruszniewski, P., & Vilgrain, V. (2013) · Radiology · doi:10.1148/radiol.13121628 · Cited by 212
Wolin, E., Jarzab, B., Eriksson, B., Walter, T., Toumpanakis, C., Morse, M. A., Tomassetti, P., Weber, M. M., Fogelman, D., Ramage, J., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s84177 · Cited by 210
Self-citationPIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Meric-Bernstam, F., Akcakanat, A., Chen, H., Do, K.-A., Sangai, T., Adkins, F., Gonzalez-Angulo, A. M., Rashid, A., Crosby, K., Dong, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2123 · Cited by 208
Faivre, S., Niccoli, P., Castellano, D., Valle, J. W., Hammel, P., Raoul, J.-L., Vinik, A., Van Cutsem, E., Bang, Y.-J., Lee, S.-H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw561 · Cited by 194
Interferon in the Management of Neuroendocrine GEP-Tumors
Öberg, K. (2000) · Digestion · doi:10.1159/000051862 · Cited by 187
Self-citationPreoperative Detection of Pancreatic Insulinomas on Multiphasic Helical CT
Fidler, J. L., Fletcher, J. G., Reading, C. C., Andrews, J. C., Thompson, G. B., Grant, C. S., & Service, F. J. (2003) · American Journal of Roentgenology · doi:10.2214/ajr.181.3.1810775 · Cited by 187
Partelli, S., Cirocchi, R., Crippa, S., Cardinali, L., Fendrich, V, Bartsch, D. K., & Falconi, M. (2017) · Journal of British Surgery · doi:10.1002/bjs.10312 · Cited by 174
Self-citationCives, M., Ghayouri, M., Morse, B., Brelsford, M., Black, M., Rizzo, A., Meeker, A., & Strosberg, J. (2016) · Endocrine-Related Cancer · doi:10.1530/erc-16-0147 · Cited by 167
Yao, J. C., Guthrie, K. A., Moran, C., Strosberg, J. R., Kulke, M. H., Chan, J. A., LoConte, N., McWilliams, R. R., Wolin, E. M., Mattar, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.4072 · Cited by 166
Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms
Leoncini, E., Boffetta, P., Shafir, M. K., Aleksovska, K., Boccia, S., & Rindi, G. (2017) · Endocrine · doi:10.1007/s12020-017-1273-x · Cited by 159
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
Carlsen, E. A., Fazio, N., Granberg, D., Grozinsky-Glasberg, S., Ahmadzadehfar, H., Grana, C. M., Zandee, W. T., Cwikla, J., Walter, M. A., Oturai, P. S., et al. (2019) · Endocrine-Related Cancer · doi:10.1530/erc-18-0424 · Cited by 159
Zandee, W. T., Brabander, T., Blažević, A., Kam, B. L. R., Teunissen, J. J. M., Feelders, R. A., Hofland, J., & de Herder, W. W. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01991 · Cited by 155
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial
Pavel, M., Gross, D. J., Benavent, M., Perros, P., Srirajaskanthan, R., Warner, R. R. P., Kulke, M. H., Anthony, L. B., Kunz, P. L., Hörsch, D., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0455 · Cited by 141
Self-citationPRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy
Bodei, L., Kidd, M. S., Singh, A., van der Zwan, W. A., Severi, S., Drozdov, I. A., Ćwikła, J. B., Baum, R. P., Kwekkeboom, D. J., Paganelli, G., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3967-6 · Cited by 139
Self-citationKnigge, U., Capdevila, J., Bartsch, D. K., Baudin, E., Falkerby, J., Kianmanesh, R., Kos-Kudla, B., Niederle, B., Nieveen van Dijkum, E., O'Toole, D., et al. (2017) · Neuroendocrinology · doi:10.1159/000458155 · Cited by 136 · cited 5×
“PRRT is a therapeutic option in progressive SSTR-positive NETs with homogenous SSTR expression (all NET lesions are positive) assessed by SSTR imaging [91, 92].”
InfluentialSelf-citationZhang, J., Kulkarni, H., Singh, A., Niepsch, K., Müller, D., & Baum, R. P. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.215848 · Cited by 132
Pavel, M. E., Baudin, É., Öberg, K. E., Hainsworth, J. D., Voi, M., Rouyrre, N., Peeters, M., Gross, D. J., & Yao, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx193 · Cited by 128
Self-citationA meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood
Öberg, K., Califano, A., Strosberg, J., Ma, S., Pape, U., Bodei, L., Kaltsas, G., Toumpanakis, C., Goldenring, J. R., Frilling, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.003 · Cited by 125
Self-citationDaskalakis, K., Karakatsanis, A., Hessman, O., Stuart, H., Welin, S., Janson, E. T., Öberg, K., Hellman, P., Norlén, O., & Stalberg, P. L. H. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3326 · Cited by 119
Self-citationTreatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies
Ito, T., Lee, L., & Jensen, R. T. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1236916 · Cited by 107
Kulke, M. H., Ruszniewski, P. B., Cutsem, E. V., Lombard‐Bohas, C., Valle, J. W., de Herder, W. W., Pavel, M. E., Degtyarev, E., Brase, J. C., Bubuteishvili‐Pacaud, L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx078 · Cited by 107
Self-citationPavel, M. E., Singh, S., Strosberg, J., Bubuteishvili‐Pacaud, L., Degtyarev, E., Neary, M. P., Carnaghi, C., Tomášek, J., Wolin, E. M., Raderer, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30471-0 · Cited by 93
Self-citationBrenner, R., Metens, T., Bali, M. A., Demetter, P., & Matos, C. (2012) · European Journal of Radiology · doi:10.1016/j.ejrad.2012.01.032 · Cited by 86
Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms
Cho, C. S., Labow, D. M., Tang, L. H., Klimstra, D. S., Loeffler, A. G., LEVERSON, G. E., Fong, Y., Jarnagin, W. R., D'Angelica, M. I., Weber, S. M., et al. (2008) · Cancer · doi:10.1002/cncr.23523 · Cited by 81
Changes in the Epidemiology of Neuroendocrine Tumours
Huguet, I., Grossman, A. B., & O’Toole, D. (2015) · Neuroendocrinology · doi:10.1159/000441897 · Cited by 80
Chua, T. C., Yang, T. X., Gill, A. J., & Samra, J. S. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4826-3 · Cited by 74
Naswa, N., Sharma, P., Gupta, S. K., Karunanithi, S., Reddy, R. M., Patnecha, M., Lata, S., Kumar, R., Malhotra, A., & Bal, C. S. (2013) · Clinical Nuclear Medicine · doi:10.1097/rlu.0b013e31827a216b · Cited by 74
Ronot, M., Clift, A. K., Baum, R. P., Singh, A., Kulkarni, H., Frilling, A., & Vilgrain, V. (2017) · Neuroendocrinology · doi:10.1159/000479293 · Cited by 65
Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary
Singh, S., Carnaghi, C., Buzzoni, R., Pommier, R. F., Raderer, M., Tomášek, J., Lahner, H., Valle, J. W., Voi, M., Bubuteishvili‐Pacaud, L., et al. (2017) · Neuroendocrinology · doi:10.1159/000477585 · Cited by 60
Self-citationPellat, A., Dreyer, C., Couffignal, C., Walter, T., Lombard‐Bohas, C., Niccoli, P., Seitz, J. F., Hentic, O., André, T., Coriat, R., et al. (2018) · Neuroendocrinology · doi:10.1159/000487237 · Cited by 60
van Treijen, M. J. C., Korse, C. M., van Leeuwaarde, R. S., Saveur, L. J., Vriens, M. R., Verbeek, W. H. M., Tesselaar, M. E. T., & Valk, G. D. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00740 · Cited by 59
Metachronous Hormonal Syndromes in Patients With Pancreatic Neuroendocrine Tumors
de Mestier, L., Hentic, O., Cros, J. F., Walter, T., Roquin, G., Brixi, H., Lombard‐Bohas, C., Hammel, P. R., Diébold, M.-D., Couvelard, A., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2132 · Cited by 55
Vinik, A. I., Bottomley, A., Korytowsky, B., et al. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0462-5 · Cited by 52
Severi, S., Grassi, I., Nicolini, S., Sansovini, M., Bongiovanni, A., & Paganelli, G. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s97584 · Cited by 48
van Adrichem, R. C. S., Kamp, K., van Deurzen, C. H. M., Biermann, K., Feelders, R. A., Franssen, G. J. H., Kwekkeboom, D. J., Hofland, L. J., & de Herder, W. W. (2015) · Neuroendocrinology · doi:10.1159/000441604 · Cited by 38
Cella, D. F., Beaumont, J. L., Hudgens, S. A., Marteau, F., Feuilly, M., Houchard, A., Lapuerta, P., Ramage, J. K., Pavel, M. E., Hörsch, D., et al. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.10.008 · Cited by 33
Self-citationXu, J., Shen, L., Zhou, Z., Li, J., Bai, C., Chi, Y., Li, Z., Xu, N., Jia, R., Li, E., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz394.073 · Cited by 18
Cited by
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Conroy, T., Pfeiffer, P., Vilgrain, V., Lamarca, A., Seufferlein, T., O’Reilly, E. M., Hackert, T., Golan, T., Prager, G., Haustermans, K., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.08.009 · Cited by 610
Strosberg, J. R., Caplin, M. E., Kunz, P. L., Ruszniewski, P. B., Bodei, L., Hendifar, A., Mittra, E., Wolin, E. M., Yao, J. C., Pavel, M. E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00572-6 · Cited by 578
Self-citationSingh, S., Halperin, D., Myrehaug, S., Herrmann, K., Pavel, M., Kunz, P. L., Chasen, B., Tafuto, S., Lastoria, S., Capdevila, J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00701-3 · Cited by 386
Self-citationBaudin, E., Caplin, M., Garcia-Carbonero, R., Fazio, N., Ferolla, P., Filosso, P. L., Frilling, A., de Herder, W. W., Hörsch, D., Knigge, U., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.003 · Cited by 270
Self-citationXu, Z., Wang, L., Dai, S., Chen, M., Li, F., Sun, J., & Luo, F. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24750 · Cited by 264
Metadata
- Authors
- Pavel, M., Öberg, K., Falconi, M., Krenning, E. P., Sundin, A., Perren, A., & Berruti, A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 31
- Issue
- 7
- Pages
- 844-860
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3015314028
- Cited by
- 1,179
- References
- 78
- FWCI
- 89.08
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.